BRIEF — Bristol-Myers Squibb and Flatiron Health expand collaboration with three-year agreement

B-MS will use Flatiron’s real-world data to accelerate its research and development efforts, as well as improve its ability to generate additional evidence on the use of its cancer medicines outside of clinical trials. With the expanded collaboration, the two companies intend to form a joint Scientific Advisory Board to advance the use of RWE for regulatory decision making.

“Our continued collaboration with Flatiron further strengthens our comprehensive RWE capabilities, an important component of our oncology drug development program, giving us greater insight into the use and impact of our cancer therapies,” said Thomas Lynch, executive vice president and chief scientific officer at B-MS.

“We will work with Flatiron to contribute to RWE industry guidance and standards, and advance new regulatory-focused RWE use cases. Ultimately, this work will enable us to accelerate our ability to help patients.”

Flatiron is the company that is to be acquired by Swiss pharma giant Roche, it was announced in February.